Eribulin increases Tumour Perfusion and
Reoxygenation in Metastatic Breast Cancer
Eribulin’s and Bevacizumab’s tumour microvasculature remodelling
capabilities were assayed in 30 ABC patients using DCE-MRI and perfusion
biomarkers
Ueda S, et al.
Br J Cancer
. 2016
Bevacizumab significantly
reduced Oxyhaemoglobin, Deoxyhaemoglobin, and VEGF.
These findings correlate with
a strong
antiangiogenic process
Eribulin, but not Bevacizumab, statistically
increased Oxyhaemoglobin and Oxygen Saturation while decreased
expression of VEGF and TGFβ.
These findings correlate with a complex
microvasculature remodelling process
Oxyhaemoglobin
Deoxyhaemoglobin
O
2
Saturation
VEGF
TGFβ
Haemodynamic biomarkers
Molecular biomarkers
